The upgrade from 'Hold' to 'Buy' is a strong positive signal for Zai Lab's stock, indicating confidence in its future performance. The company's strategy of in-licensing U.S.-approved drugs for the Chinese market is proving successful, with key products driving revenue growth. Despite high costs, the consistent revenue growth and strong cash position suggest that the company is well-positioned for future success.